Cytosorbents (CTSO) Metrics: History & Chart

Cytosorbents Corporation(CTSO)

Medical - Devices · Princeton, NJ

$4.07+0.11 (+2.65%)

Delayed quote: Oct 6, 2026, 3:59 PM EDT

About Cytosorbents Corporation

Cytosorbents Corporation specializes in creating and bringing to market innovative medical devices. Their core expertise lies in a unique blood purification platform, built upon a proprietary adsorbent and porous polymer technology. The company's leading product, CytoSorb, is an extracorporeal filter designed to remove cytokines from the blood. It serves as a complementary treatment in various critical care scenarios, including sepsis, managing complications during and after heart bypass surgery, and improving the viability of donor organs for transplantation. Beyond CytoSorb, Cytosorbents offers a portfolio of specialized devices. These include VetResQ, used to assist in treating critical conditions like sepsis and pancreatitis in animals; CytoSorb-XL, another device targeting sepsis and other severe illnesses; HemoDefend, a platform for purifying blood supplies by removing contaminants that cause transfusion reactions and diseases, as well as anti-A and anti-B antibodies from blood products; K+ontrol, designed for patients with severe, life-threatening hyperkalemia; and ContrastSorb, which extracts intravenous contrast agents following imaging procedures (like CT scans, angiograms, or interventional radiology) to mitigate the risk of contrast-induced kidney damage. The company is also actively developing several new solutions: BetaSorb, aimed at preventing and treating complications from metabolic toxin buildup in chronic kidney disease patients; DrugSorb, which focuses on eliminating harmful chemicals from the bloodstream; and DrugSorb-ATR, an innovative system for removing antithrombotic agents. Originally established as MedaSorb Technologies Corporation in 1997, the company adopted its current name, Cytosorbents Corporation, in May 2010. Its corporate headquarters are situated in Princeton, New Jersey.

Princeton, NJ

129 employees

www.cytosorbents.com

Healthcare / Medical - Devices

Sector: Healthcare
Industry: Medical - Devices
CEO: Phillip Chan

View full financials

Third-Party DCF Estimate (FMP)	N/A
Price Gap vs Third-Party Estimate	N/A

7D Total Return	-1.24%
30D Total Return	-43.29%
YTD Total Return	-68.94%
1Y Total Return	-79.83%
3Y Total Return	-87.67%
5Y Total Return	-97.52%
10Y Total Return	-96.61%
15Y Total Return	-95.27%
20Y Total Return	-99.52%

2026	-68.94%
2025	-29.78%
2024	-18.02%
2023	-28.39%
2022	-63.01%
2021	-47.43%
2020

CAGR TTM	-79.67%
CAGR 3Y	-50.22%
CAGR 5Y	-52.26%
CAGR 10Y	-28.72%
CAGR 15Y	-18.41%
CAGR 20Y	-23.42%

PE Ratio	N/A
PE Ratio Avg TTM	N/A
PE Ratio Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

All Metrics

CTSO Valuation Metrics

CTSO Stock Price Metrics

CTSO Dividend Metrics

CTSO Growth Rate Metrics

CTSO Discounted Cash Flow Metrics

CTSO Returns By Period

CTSO Yearly Returns

CTSO Average Annual Returns By Period (CAGR)

CTSO Revenue Metrics

CTSO PE Ratio Metrics

CTSO PS Ratio Metrics

CTSO PB Ratio Metrics

CTSO Price to Free Cash Flow Ratio Metrics

CTSO Debt to Equity Ratio Metrics

CTSO PEG Ratio Metrics

CTSO FCF Yield

CTSO Earnings Yield

CTSO EBITDA Yield

CTSO OCF Yield

CTSO EV/EBIT Ratio Metrics

CTSO EV/EBITDA Ratio Metrics

CTSO EV/Assets Ratio Metrics

CTSO EV/Sales Ratio Metrics

CTSO Current Ratio Metrics

CTSO Quick Ratio Metrics

CTSO ROIC Metrics

CTSO Return on Assets Metrics

CTSO Return on Equity Metrics

CTSO Net Profit Margin Metrics

CTSO Gross Profit Margin Metrics

CTSO Tax Rate Metrics

PS Ratio	0.33
PS Ratio Avg TTM	0.98
PS Ratio Avg 3Y	1.40
Current VS TTM Avg	-66.41%
Current VS 3Y Avg	-76.36%
Current VS 5Y Avg	-83.20%

PB Ratio	11.40
PB Ratio Avg TTM	5.22
PB Ratio Avg 3Y	3.97
Current VS TTM Avg	+118.21%
Current VS 3Y Avg	+187.41%
Current VS 5Y Avg	+221.78%

PFCF Ratio	N/A
PFCF Ratio Avg TTM	N/A
PFCF Ratio Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

Debt/Equity Ratio	(35.07)
Debt/Equity Ratio Avg TTM	(3.23)
Debt/Equity Ratio Avg 3Y	1.67
Current VS TTM Avg	-985.82%
Current VS 3Y Avg	-2196.57%
Current VS 5Y Avg	-3364.59%

PEG Ratio	N/A
PEG Ratio Avg TTM	N/A
PEG Ratio Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

FCF Yield	N/A
FCF Yield Avg TTM	N/A
FCF Yield Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

Earnings Yield	N/A
Earnings Yield Avg TTM	N/A
Earnings Yield Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

EBITDA Yield	N/A
EBITDA Yield Avg TTM	N/A
EBITDA Yield Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

OCF Yield	N/A
OCF Yield Avg TTM	N/A
OCF Yield Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

Ev/Ebit Ratio	N/A
Ev/Ebit Ratio Avg TTM	N/A
Ev/Ebit Ratio Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

Ev/Ebitda Ratio	N/A
Ev/Ebitda Ratio Avg TTM	N/A
Ev/Ebitda Ratio Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

Ev/Assets Ratio	0.91
Ev/Assets Ratio Avg TTM	1.26
Ev/Assets Ratio Avg 3Y	1.36
Current VS TTM Avg	-27.61%
Current VS 3Y Avg	-33.22%
Current VS 5Y Avg	-33.21%

Ev/Sales Ratio	0.92
Ev/Sales Ratio Avg TTM	1.49
Ev/Sales Ratio Avg 3Y	1.84
Current VS TTM Avg	-38.29%
Current VS 3Y Avg	-50.07%
Current VS 5Y Avg	-53.13%

Current Ratio	0.66
Current Ratio Avg TTM	1.66
Current Ratio Avg 3Y	1.98
Current VS TTM Avg	-60.60%
Current VS 3Y Avg	-66.84%
Current VS 5Y Avg	-73.05%

Quick Ratio	0.50
Quick Ratio Avg TTM	1.31
Quick Ratio Avg 3Y	1.65
Current VS TTM Avg	-61.81%
Current VS 3Y Avg	-69.52%
Current VS 5Y Avg	-76.18%

ROIC	(43.31%)
ROIC Avg 3Y	(54.61%)
ROIC Avg 5Y	(50.33%)
Current VS 3Y Avg	+20.69%
Current VS 5Y Avg	+13.94%
Current VS 10Y Avg	+16.37%

ROA	(47.98%)
ROA Avg TTM	(7.92%)
ROA Avg 3Y	(10.97%)
Current VS TTM Avg	-505.89%
Current VS 3Y Avg	-337.39%
Current VS 5Y Avg	-350.23%

ROE	N/A
ROE Avg TTM	(198.08%)
ROE Avg 3Y	(128.99%)
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

Net Profit Margin	(48.94%)
Net Profit Margin Avg TTM	(35.28%)
Net Profit Margin Avg 3Y	(59.21%)
Current VS TTM Avg	-38.70%
Current VS 3Y Avg	+17.35%
Current VS 5Y Avg	+19.55%

Gross Profit Margin	71.61%
Gross Pft Margin Avg TTM	71.43%
Gross Pft Margin Avg 3Y	71.02%
Current VS TTM Avg	+0.25%
Current VS 3Y Avg	+0.83%
Current VS 5Y Avg	+5.27%

Tax Rate	0.00%
Tax Rate Avg 3Y	N/A
Tax Rate Avg 5Y	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A
Current VS 10Y Avg	N/A